ESC: Ivabradine Flops in CAD Trial (CME/CE)

BARCELONA (MedPage Today) -- Ivabradine, a novel heart-rate reducing agent, increased the likelihood of death or heart attack when given to patients with activity-limiting angina who were already receiving standard background therapy for stable coronary artery disease. via MedPageToday.com - medical news plus CME for physicians Read More Here..

For a Free Step By Step Guide for Dating Dos and Don'ts check http://end2endwebs.com

Lake forest health and fitness http://ift.tt/1wWyeHN